Medivolve Inc. (MEDVF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Medivolve Inc. (MEDVF) trades at $0.00 with AI Score 45/100 (Grade C). Medivolve Inc. is a Canadian primary investment firm established in 2005, focusing its capital predominantly on healthcare technology, industrial enterprises, and information technology. Market cap: $2,702, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for MEDVF: MEDVF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MEDVF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MEDVF: the 1 perspectives are evenly split.
How is this calculated? →Medivolve Inc. (MEDVF) Healthcare & Pipeline Overview
Medivolve Inc. is a Toronto-based primary investment firm established in 2005, deploying capital across healthcare technology, industrial, and information technology sectors. Formerly QuestCap Inc., it also engages in telemedicine and virtual health solutions, aiming to provide accessible healthcare services through technology, operating within the dynamic healthcare landscape.
What Is the Investment Thesis for MEDVF?
Medivolve Inc. presents an investment thesis centered on its dual role as a primary investment firm and an operator in the healthcare technology sector. A key value driver is its strategic allocation of capital into high-growth areas like healthcare technology, industrial enterprises, and information technology, aiming to capitalize on sector-specific innovations and market expansion. The company's operational focus on telemedicine and virtual health solutions positions it to benefit from the ongoing secular trend towards remote healthcare, a market experiencing significant expansion. The growing demand for accessible healthcare services through technology represents a substantial growth catalyst, with the global telehealth market projected to continue its robust growth trajectory in the coming years. However, the company's negative profit margin of -2397.5% indicates significant unprofitability, while its high gross margin of 78.3% suggests strong pricing power or efficient service delivery at the gross level, but substantial operating expenses. A beta of 2.73 signifies high volatility relative to the broader market. Risks include the competitive landscape of the telehealth industry, the inherent risks associated with early-stage investments, and the challenges of scaling operations in a rapidly evolving technological environment. Investors should evaluate Medivolve's ability to translate its gross margin into profitability and effectively manage its investment portfolio.
Based on FMP financials and quantitative analysis
MEDVF Key Highlights
- Market Capitalization: $0.00 billion, indicating a micro-cap or nano-cap valuation.
- Profit Margin: -2397.5%, reflecting substantial net losses relative to revenue.
- Gross Margin: 78.3%, demonstrating strong profitability at the gross level before operating expenses.
- Beta: 2.73, indicating significantly higher volatility compared to the overall market.
- Employee Count: 25 employees, suggesting a lean operational structure for an investment firm and healthcare technology operator.
Who Are MEDVF's Competitors?
MEDVF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
| TWST Twist Bioscience Corporation | $100.97 | +1.74% | $6.29B | 65 |
| CNTG Centogene N.V. | $0.33 | +100.00% | $9.42M | 50 |
| NVTA Invitae Corporation | $0.02 | -35.59% | $5.44M | 50 |
| ICLR ICON Public Limited Company | $170.94 | -1.23% | $13.09B | 50 |
| ME 23andMe Holding Co. | $0.61 | +100.00% | $15.31M | 50 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MEDVF's Key Strengths?
- Diversified investment focus across healthcare technology, industrial, and IT sectors.
- Direct operational engagement in the growing telemedicine and virtual health market.
- High gross margin of 78.3% indicates strong unit economics before operating expenses.
- Lean operational structure with 25 employees.
What Are MEDVF's Weaknesses?
- Significant unprofitability, evidenced by a -2397.5% profit margin.
- High stock volatility with a Beta of 2.73.
- Operates on the OTC Other tier, implying less stringent disclosure and higher risk.
- Small market capitalization ($0.00B) suggests limited access to capital markets.
What Could Drive MEDVF Stock Higher?
- Successful deployment of new healthcare technology solutions within its operational arm.
- Strategic investment in a high-growth healthcare technology or IT company yielding significant returns.
- Increasing adoption rates and market penetration of its virtual health services.
- Announcement of new partnerships or collaborations to expand its investment portfolio or telehealth reach.
What Are the Key Risks for MEDVF?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Significant unprofitability, as evidenced by a -2397.5% profit margin, posing sustainability concerns.
- Intense competition in both the investment firm landscape and the rapidly evolving telehealth market.
- High stock volatility (Beta of 2.73) leading to unpredictable share price movements.
- Challenges in securing additional capital for investments or operational expansion due to its OTC Other listing and small market cap.
- Regulatory changes in healthcare technology or investment guidelines impacting business operations and profitability.
What Are the Growth Opportunities for MEDVF?
- Expansion in Telemedicine and Virtual Health Solutions: The global telemedicine market is projected to continue its robust expansion, with estimates suggesting a market size reaching hundreds of billions of dollars by the early 2030s, growing at a CAGR exceeding 20%. Medivolve Inc.'s focus on developing and deploying virtual health solutions positions it directly within this high-growth segment. By enhancing its technological infrastructure and expanding its service offerings, the company can capture a larger share of the increasing demand for remote consultations, digital diagnostics, and virtual patient monitoring. This growth driver is supported by evolving patient preferences, regulatory support for telehealth, and the cost-efficiency benefits it offers to healthcare systems.
- Strategic Investments in Healthcare Technology: As a primary investment firm, Medivolve Inc. has the opportunity to identify and fund innovative healthcare technology startups and scale-ups. The healthcare technology market, encompassing areas like AI in diagnostics, digital therapeutics, and health data analytics, is experiencing significant venture capital inflows and rapid innovation. By making strategic investments in promising companies within this sector, Medivolve can benefit from the appreciation of its portfolio assets. This approach allows the company to diversify its exposure within healthcare and leverage the expertise of other innovators, potentially generating substantial returns as these technologies mature and gain wider adoption over the next 5-10 years.
- Diversification into Industrial and Information Technology: Medivolve's investment mandate extends beyond healthcare into industrial enterprises and information technology. These sectors also present significant growth avenues driven by digital transformation, automation, and the increasing demand for data-driven solutions. For instance, the global industrial IoT market is expected to grow substantially, and the IT services market continues to expand with cloud adoption and cybersecurity needs. By strategically allocating capital to high-potential companies within these diversified sectors, Medivolve can mitigate risks associated with over-reliance on a single industry and tap into broader economic growth trends, enhancing its overall portfolio performance and stability.
- Leveraging Data and AI in Healthcare Operations: The integration of artificial intelligence and advanced data analytics into healthcare operations presents a significant opportunity for Medivolve's telemedicine arm. AI can enhance diagnostic accuracy, personalize treatment plans, and optimize operational efficiencies in virtual care platforms. The market for AI in healthcare is projected to reach over $200 billion by the early 2030s, indicating a vast potential for innovation and value creation. By investing in and implementing AI-driven tools, Medivolve can differentiate its virtual health solutions, improve patient outcomes, and potentially reduce operational costs, thereby attracting more users and increasing its competitive advantage over the next 3-7 years.
- Geographic Expansion of Telehealth Services: While specific geographic reach is not detailed, the nature of telemedicine allows for scalable expansion into new regions or underserved markets. Many regions globally are still developing their digital health infrastructure and have significant unmet needs for accessible healthcare. By strategically identifying and entering new geographic markets, either through direct service provision or partnerships, Medivolve can tap into new patient populations and revenue streams. This expansion could involve tailoring services to local regulatory environments and healthcare demands, potentially leading to substantial market penetration and revenue growth over a 5-10 year horizon as digital health adoption becomes more ubiquitous worldwide.
What Opportunities Does MEDVF Have?
- Growing demand for remote healthcare options and digital health solutions.
- Potential for strategic acquisitions or investments in innovative healthcare technology.
- Expansion into new geographic markets for telemedicine services.
- Leveraging AI and data analytics to enhance virtual health offerings.
What Threats Does MEDVF Face?
- Intense competition in both the investment and telehealth sectors.
- Regulatory changes impacting telemedicine or investment activities.
- Economic downturns affecting investment valuations and consumer spending on healthcare.
- Challenges in scaling operations and managing high operating costs.
What Are MEDVF's Competitive Advantages?
- Diversified investment strategy across multiple high-growth technology sectors.
- Early mover advantage or established presence in specific niches of healthcare technology and telemedicine.
- Strategic partnerships and network within the investment and healthcare technology ecosystems.
- Potential for proprietary technology or unique service delivery models in its virtual health operations.
What Does MEDVF Do?
Medivolve Inc., headquartered in Toronto, Canada, commenced operations in 2005 as QuestCap Inc. Over its history, the firm has evolved into a primary investment entity, strategically allocating capital across a diversified portfolio of sectors. Its core investment focus lies predominantly within the high-growth domains of healthcare technology, industrial enterprises, and information technology. This multi-sector investment approach allows Medivolve to capitalize on innovation and market expansion across various industries. Beyond its role as an investment firm, Medivolve Inc. has also established a direct operational presence within the healthcare sector, specifically concentrating on telemedicine and virtual health solutions. This operational arm is dedicated to leveraging technological advancements to enhance the accessibility and delivery of healthcare services. The company's strategic pivot or expansion into direct healthcare operations aligns with the broader industry trend towards digital transformation and remote patient care. By investing in and operating within healthcare technology, Medivolve aims to address the increasing demand for convenient and efficient medical services, particularly those facilitated by virtual platforms. Its Toronto base positions it within a vibrant North American innovation ecosystem, allowing it to identify and engage with promising ventures and market opportunities. The company's dual strategy of direct healthcare operations and diversified investment in technology and industrial sectors provides a unique market position, seeking to generate value through both active management and strategic capital deployment. This structure allows Medivolve to participate in the growth of its portfolio companies while also developing its own operational capabilities in a critical sector. The firm's relatively small employee base of 25 suggests a lean operational model, likely relying on strategic partnerships and efficient capital allocation to drive its initiatives.
What Products and Services Does MEDVF Offer?
- Operates as a primary investment firm.
- Invests capital predominantly in healthcare technology companies.
- Allocates funds to industrial enterprises.
- Channels investments into information technology firms.
- Focuses on telemedicine and virtual health solutions within the healthcare sector.
- Aims to provide accessible healthcare services through technology.
- Engages in strategic capital deployment across diversified high-growth sectors.
How Does MEDVF Make Money?
- Generating returns through strategic equity investments in healthcare technology, industrial, and information technology companies.
- Earning revenue from the provision of telemedicine and virtual health services.
- Potentially realizing capital gains from the successful exits or growth of its portfolio companies.
- Leveraging technology to create scalable healthcare solutions that attract users and generate service fees.
What Industry Does MEDVF Operate In?
Medivolve Inc. operates within the dynamic and rapidly evolving healthcare sector, specifically engaging with the Medical - Diagnostics & Research industry through its healthcare technology investments and telemedicine operations. The broader healthcare market is experiencing significant trends, including the increasing adoption of digital health solutions, a growing emphasis on preventative care, and the persistent demand for accessible and efficient medical services. Telemedicine, a core focus for Medivolve, has seen accelerated growth, particularly post-pandemic, driven by technological advancements and shifting consumer preferences for remote consultations. This segment of the healthcare technology market is highly competitive, featuring both established players and numerous agile startups. Medivolve's positioning as both an investment firm and an operator allows it to participate in this growth by identifying and funding innovative solutions while also directly contributing to the telehealth landscape. The company aims to carve out its niche by leveraging technology to enhance healthcare accessibility, navigating a landscape characterized by rapid innovation and evolving regulatory frameworks.
Who Are MEDVF's Key Customers?
- Companies seeking strategic investment and growth capital in healthcare technology, industrial, and information technology sectors.
- Patients and individuals seeking accessible and convenient virtual healthcare services.
- Healthcare providers looking for technological solutions to enhance service delivery.
- Potentially, institutional investors and partners interested in co-investments or strategic alliances.
Company Profile
Medivolve Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO Neil Said. MEDVF has traded publicly since 2009.
Medivolve Inc. (MEDVF) Valuation Context
Valued at 3K, MEDVF is classified as a micro-cap stock. Relative to its peer group, MEDVF's quantitative score of 45/100 is below the peer average of 64/100.
ROE 213%Key Financial Metrics
Return on equity for Medivolve Inc. stands at 213.2%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.08 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 2/9Financial Health
Medivolve Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
MEDVF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Diversified investment focus across healthcare technology, industrial, and IT sectors.
- Direct operational engagement in the growing telemedicine and virtual health market.
- High gross margin of 78.3% indicates strong unit economics before operating expenses.
- Lean operational structure with 25 employees.
Bear Case
- Significant unprofitability, evidenced by a -2397.5% profit margin.
- High stock volatility with a Beta of 2.73.
- Operates on the OTC Other tier, implying less stringent disclosure and higher risk.
- Small market capitalization ($0.00B) suggests limited access to capital markets.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
MEDVF Latest News
No recent news available for MEDVF.
MEDVF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MEDVF.
Price Targets
Wall Street price target analysis for MEDVF.
MEDVF MoonshotScore
What does this score mean?
The MoonshotScore rates MEDVF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Neil Said
Chief Executive Officer
Neil Said serves as the Chief Executive Officer of Medivolve Inc., leading the company's strategic direction and overseeing its team of 25 employees. Specific details regarding Mr. Said's extensive career history, educational background, and previous executive roles prior to joining Medivolve Inc. are not publicly available in the provided source data. His leadership is pivotal in guiding the company's dual mandate as a primary investment firm focusing on healthcare technology, industrial, and information technology sectors, as well as its operational involvement in telemedicine and virtual health solutions.
Track Record: Under Neil Said's leadership, Medivolve Inc. has continued its evolution as a primary investment firm and expanded its focus into telemedicine. Specific key achievements, strategic decisions, or company milestones directly attributable to his tenure are not detailed in the provided information. His role involves navigating the complexities of both strategic investments and operational growth within the dynamic healthcare technology landscape.
MEDVF OTC Market Information
Medivolve Inc. trades on the OTC Other tier, which represents the lowest and most speculative segment of the OTC market. Unlike companies listed on major exchanges such as the NYSE or NASDAQ, which adhere to stringent listing standards regarding financial health, corporate governance, and minimum share prices, OTC Other companies have minimal to no public disclosure requirements. This tier is typically home to shell companies, dormant companies, or those with financial distress, making them highly speculative. Investors face significantly higher risks due to the lack of transparency and regulatory oversight compared to higher OTC tiers like OTCQX or OTCQB, which have more robust reporting standards.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Lack of public financial disclosure, making fundamental analysis challenging.
- Extremely low liquidity and wide bid-ask spreads, hindering efficient trading.
- High susceptibility to market manipulation due to minimal oversight.
- Difficulty in obtaining reliable price quotes and company information.
- Potential for delisting or further regulatory actions due to non-compliance.
- Verify current financial statements and audit reports, if any are available.
- Research management's background, track record, and any past regulatory issues.
- Investigate any recent news, press releases, or corporate actions.
- Assess the company's business model and competitive landscape thoroughly.
- Understand the specific risks associated with the OTC Other tier.
- Seek independent legal and financial advice before investing.
- Attempt to find any available regulatory filings from Canadian authorities.
- Established in 2005, indicating a longer operational history than many shell companies.
- Identified CEO, Neil Said, provides a clear point of leadership.
- Specific business description as a primary investment firm with sector focus.
- Operational involvement in telemedicine, suggesting active business pursuits.
MEDVF Healthcare Stock FAQ
What does Medivolve Inc. do?
Medivolve Inc. operates as a primary investment firm based in Toronto, Canada, established in 2005. The company strategically allocates capital across three main sectors: healthcare technology, industrial enterprises, and information technology. Beyond its investment activities, Medivolve Inc. also has an operational focus within the healthcare sector, specifically developing and deploying telemedicine and virtual health solutions. Its objective is to leverage technology to enhance the accessibility and efficiency of healthcare services. This dual business model allows Medivolve to participate in the growth of various high-potential industries through its investment portfolio while also directly contributing to the evolving landscape of digital healthcare.
What are Medivolve Inc.'s revenue streams in healthcare and technology?
Medivolve Inc. generates revenue primarily through two distinct avenues. As a primary investment firm, its revenue streams are derived from capital gains and potential dividends or interest from its diversified portfolio of investments in healthcare technology, industrial, and information technology companies. The success of these investments, including successful exits or appreciation in portfolio company valuations, directly contributes to its financial performance. Additionally, through its operational focus on telemedicine and virtual health solutions, Medivolve generates revenue from the provision of these healthcare services. This could include fees for virtual consultations, subscription models for health platforms, or other service-related charges for accessible healthcare through technology.
What are the main risks for Medivolve Inc. given its operational and investment model?
Medivolve Inc. faces several key risks stemming from its dual operational and investment model. Operationally, the company contends with intense competition within the rapidly expanding telemedicine and virtual health markets, requiring continuous innovation and significant marketing efforts. Financially, a substantial ongoing risk is its reported -2397.5% profit margin, indicating significant unprofitability that could challenge long-term sustainability. As an investment firm, it is exposed to market volatility and the inherent risks associated with early-stage or growth-stage investments, where capital preservation and return generation are not guaranteed. Furthermore, its listing on the OTC Other tier introduces risks related to limited disclosure, low liquidity, and potential for market manipulation, which can impact investor confidence and access to capital.
What are the key factors to evaluate for MEDVF?
Medivolve Inc. (MEDVF) holds an AI score of 45/100 (low). Not financial advice.
How frequently does MEDVF data refresh on this page?
MEDVF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven MEDVF's recent stock price performance?
Medivolve Inc. (MEDVF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified investment focus across healthcare technology, industrial, and IT sectors. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MEDVF overvalued or undervalued right now?
Valuing Medivolve Inc. (MEDVF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying MEDVF?
Before investing in Medivolve Inc. (MEDVF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited specific details on CEO's background and track record.
- No FMP PEER TICKERS provided, so competitors are listed as 'Unknown'.
- Specific market sizes and timelines for growth opportunities are generalized based on industry trends due to lack of company-specific data.
- No analyst ratings or price targets were provided in the source data, so the analyst consensus FAQ was omitted and replaced with a company-fundamentals FAQ.